MX338151B - Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. - Google Patents

Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Info

Publication number
MX338151B
MX338151B MX2011011163A MX2011011163A MX338151B MX 338151 B MX338151 B MX 338151B MX 2011011163 A MX2011011163 A MX 2011011163A MX 2011011163 A MX2011011163 A MX 2011011163A MX 338151 B MX338151 B MX 338151B
Authority
MX
Mexico
Prior art keywords
antibodies
antibody compositions
growth factor
factor receptor
epidermal growth
Prior art date
Application number
MX2011011163A
Other languages
English (en)
Inventor
Lucilla Steinaa
Klaus Koefoed
Per-Johan Meijer
Lars Soegaard Nielsen
Mikkel Wandahl Pedersen
Allan Jensen
Robert Carlsson
Charles Pyke
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338151(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX338151B publication Critical patent/MX338151B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición de anticuerpos anti-EGFR caracterizada porque comprende al menos dos anticuerpos anti-EGFR distintos, en donde al menos uno de los anticuerpos anti-EGFR se selecciona de: (a) un anticuerpo que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 40 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO: 72 DE 992, y (b) un anticuerpo que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 41 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ LID NO: 73 DE 1024. Una composición farmacéutica que comprende la composición de anticuerpos anti-EGFR y un excipiente farmacéuticamente aceptable para usarse en la terapia del cáncer, en donde la composición está adaptada para ser administrable de forma simultánea, separada o sucesiva en la terapia del cáncer. Un anticuerpo aislado caracterizado porque comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 40 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO: 72 de 992. Un anticuerpo aislado que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 41 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO:73 de 1,024.
MX2011011163A 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. MX338151B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11
PCT/DK2008/050047 WO2008104183A2 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (1)

Publication Number Publication Date
MX338151B true MX338151B (es) 2016-04-05

Family

ID=39495833

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011011163A MX338151B (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
MX2009008909A MX2009008909A (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009008909A MX2009008909A (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Country Status (18)

Country Link
US (3) US7887805B2 (es)
EP (2) EP2725036B1 (es)
JP (1) JP5726417B2 (es)
KR (2) KR101676622B1 (es)
CN (2) CN104151430A (es)
AU (1) AU2008221118B2 (es)
BR (1) BRPI0808551B1 (es)
CA (1) CA2676049C (es)
DK (1) DK2132229T3 (es)
ES (1) ES2582386T3 (es)
HK (1) HK1197252A1 (es)
IL (2) IL199725A (es)
MX (2) MX338151B (es)
NZ (2) NZ597466A (es)
PL (1) PL2132229T3 (es)
RU (1) RU2013119724A (es)
TW (1) TWI426083B (es)
WO (1) WO2008104183A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN104151430A (zh) 2007-03-01 2014-11-19 西福根有限公司 重组抗表皮生长因子受体抗体组合物
RU2459868C2 (ru) * 2007-03-01 2012-08-27 Симфоген А/С Способ клонирования когнатных антител
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
WO2009086411A2 (en) * 2007-12-27 2009-07-09 Abbott Laboratories Negative mimic antibody for use as a blocking reagent in bnp immunoassays
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
CA2739476A1 (en) * 2008-10-06 2010-04-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
US20120264155A1 (en) 2009-10-09 2012-10-18 Symphogen A/S Multiplex Quantitation of Individual Recombinant Proteins in a Mixture by Signature Peptides and Mass Spectrometry
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
EP2563393B1 (en) 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
SG185366A1 (en) * 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2635605B1 (en) * 2010-11-01 2018-07-25 Symphogen A/S Anti-her3 antibodies and compositions
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012100346A1 (en) * 2011-01-24 2012-08-02 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
CN103842379A (zh) 2011-03-09 2014-06-04 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
SG192844A1 (en) 2011-03-11 2013-09-30 Merrimack Pharmaceuticals Inc Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
BR112013022887A2 (pt) 2011-03-15 2016-12-06 Merrimack Pharmaceuticals Inc superação de resistência a inibidores de via de erbb
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
MX2014006087A (es) 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
US20150011431A1 (en) * 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
HK1226081A1 (zh) * 2013-09-12 2017-09-22 Halozyme, Inc. 修饰的抗表皮生长因子受体抗体及其使用方法
CN106170299A (zh) * 2014-01-22 2016-11-30 小利兰斯坦福大学托管委员会 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物
GB201402591D0 (en) * 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
AU2015236288A1 (en) * 2014-03-26 2016-09-15 Siemens Healthcare Diagnostics Inc. Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3223857A4 (en) * 2014-10-31 2018-06-27 Formation Biologics Inc. Egfr antibody-based combination therapy
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
AU2016252877A1 (en) 2015-04-24 2017-11-09 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (EGFR) with a combination of three fully human monoclonal anti-EGFR antibodies
CN109310754A (zh) 2016-03-15 2019-02-05 梅里麦克制药股份有限公司 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
KR20240133790A (ko) * 2016-12-23 2024-09-04 비스테라, 인크. 결합 폴리펩타이드 및 이의 제조 방법
WO2018152634A1 (en) * 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
WO2019043059A1 (en) 2017-08-30 2019-03-07 Symphogen A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
AU2019211411B2 (en) * 2018-01-25 2025-11-27 Cullinan Mica Corp. MICA/B antibodies and methods of use
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US12162747B2 (en) 2018-12-03 2024-12-10 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
CA3233771A1 (en) 2021-10-04 2023-04-13 Les Laboratoires Servier Cancer therapy targeting nkg2a
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
WO2001088138A1 (en) * 2000-05-19 2001-11-22 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
EP1361893B1 (en) 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
BRPI0210405B8 (pt) * 2001-06-13 2021-05-25 Genmab As anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
WO2003012072A2 (en) * 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
AU2003211342A1 (en) 2002-03-01 2003-09-16 Japan Envirochemicals, Ltd. Proteins capable of binding to environmental hormones and process for producing the same
AU2003236649A1 (en) 2002-05-15 2003-12-02 Falko Fend Egf receptor antagonists in the treatment of gastric cancer
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
MXPA05003796A (es) * 2002-10-10 2006-02-22 Merck Patent Gmbh Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor.
PT1583830E (pt) 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US7655751B2 (en) * 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
ES2332524T3 (es) * 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US7981605B2 (en) 2005-02-24 2011-07-19 Amgen Inc. Epidermal growth factor receptor mutations
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
JP2008535508A (ja) 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
CN101277716A (zh) 2005-04-27 2008-10-01 回而生医药科技有限公司 治疗癌症的抗体
KR101607288B1 (ko) * 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
BRPI0612814A2 (pt) * 2005-07-11 2017-06-20 Macrogenics Inc anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
AU2007222798A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
CN104151430A (zh) * 2007-03-01 2014-11-19 西福根有限公司 重组抗表皮生长因子受体抗体组合物
RU2459868C2 (ru) 2007-03-01 2012-08-27 Симфоген А/С Способ клонирования когнатных антител
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
US20110135636A1 (en) 2011-06-09
HK1197252A1 (en) 2015-01-09
US20110129855A1 (en) 2011-06-02
BRPI0808551A2 (pt) 2014-08-19
TWI426083B (zh) 2014-02-11
WO2008104183A3 (en) 2008-11-13
NZ578943A (en) 2012-09-28
JP5726417B2 (ja) 2015-06-03
ES2582386T3 (es) 2016-09-12
NZ597466A (en) 2013-08-30
EP2132229B1 (en) 2016-05-11
US8414896B2 (en) 2013-04-09
KR20100014722A (ko) 2010-02-10
IL216850A (en) 2014-06-30
IL199725A (en) 2015-06-30
US20090004192A1 (en) 2009-01-01
KR20160132132A (ko) 2016-11-16
EP2132229A2 (en) 2009-12-16
CN101675075A (zh) 2010-03-17
EP2725036B1 (en) 2017-10-25
CN101675075B (zh) 2014-06-18
CA2676049C (en) 2018-04-10
IL199725A0 (en) 2010-04-15
AU2008221118A1 (en) 2008-09-04
KR101805140B1 (ko) 2017-12-05
EP2725036A1 (en) 2014-04-30
IL216850A0 (en) 2012-01-31
DK2132229T3 (en) 2016-06-20
US7887805B2 (en) 2011-02-15
RU2013119724A (ru) 2014-11-10
MX2009008909A (es) 2009-08-28
KR101676622B1 (ko) 2016-11-17
CN104151430A (zh) 2014-11-19
TW200902552A (en) 2009-01-16
PL2132229T3 (pl) 2016-12-30
CA2676049A1 (en) 2008-09-04
WO2008104183A2 (en) 2008-09-04
JP2010535012A (ja) 2010-11-18
HK1134826A1 (zh) 2010-06-11
BRPI0808551B1 (pt) 2022-04-05
AU2008221118B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
MX338151B (es) Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
NZ599875A (en) Human il-23 antigen binding proteins
WO2010022736A3 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MY185858A (en) Specific binding proteins and uses thereof
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
MY160628A (en) Therapeutic DLL4 Binding Proteins
MX2010008060A (es) Anticuerpos humanizados especificos para el factor von willerbrand.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2009140177A3 (en) Anti-fn14 antibodies and uses thereof
PH12012502022B1 (en) Anti-erbb3 antibodies
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
ATE526987T1 (de) Dr5-antikörper und deren verwendung
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2010100056A3 (en) Antibodies against a proliferating inducing ligand (april)
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
EA201071068A1 (ru) Антитела к tyrp1
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2010080248A3 (en) Peptides that bind eukaryotic translation initiation factor 4e